Literature DB >> 16309223

Protective effect of melatonin on human peripheral blood hematopoeitic stem cells against doxorubicin cytotoxicity.

Khaled Greish1, Isao Sanada, Alla El-Dein Saad, Ehab Hasanin, Michio Kawasuji, Fumio Kawano, Hiroshi Maeda.   

Abstract

BACKGROUND: The dose-limiting toxicity of doxorubicin on hematopoietic stem cells reduces the maximum benefit from this powerful drug. Melatonin may play a role in reducing this toxicity.
MATERIALS AND METHODS: Melatonin at 10 microM was used while challenging human peripheral blood stem cells (PBSC) with doxorubicin (0.6 microM and 1 microM), and colony formation was used to evaluate the protective effect of melatonin.
RESULTS: Melatonin was protective for the myeloid and erythroid series when given during or 1 hour after, but not before, doxorubicin, as measured by colony assay. This protection was independent from its antioxidant function as measured by 2', 7'-dichlodihydro-fluorescein diacetate and was selective for PBSC when compared to the MCF-7 cancer cell line.
CONCLUSION: The results suggest the importance of the time sequence for melatonin administration to exert its protective effect in relation to doxorubicin treatment, as well as its protective effect on both erythroid and myeloid elements independent from its antioxidant function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309223

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Melatonin: does it have utility in the treatment of haematological neoplasms?

Authors:  Tian Li; Zhi Yang; Shuai Jiang; Wencheng Di; Zhiqiang Ma; Wei Hu; Fulin Chen; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-09-09       Impact factor: 8.739

2.  The Evaluation of Melatonin Effects on Mobilization and Engraftment in Autologous Hematopoietic Stem Cell Transplant Recipients; A Randomized, Double-blind and Placebo-controlled Trial.

Authors:  Neda Kazeminia; Mahshid Mehdizadeh; Jamshid Salamzadeh; Sayeh Parkhideh; Farzaneh Dastan; Arash Mahboubi; Maria Tavakoli-Ardakani
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 3.  Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.

Authors:  Javier Menéndez-Menéndez; Carlos Martínez-Campa
Journal:  Int J Endocrinol       Date:  2018-10-02       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.